Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

BACKGROUND: Pivotal phase III studies demonstrated that abrocitinib, an oral, once-daily, JAK1-selective inhibitor, is effective treatment for moderate-to-severe atopic dermatitis (AD) as monotherapy and in combination with topical therapy. OBJECTIVE: The aim of this study was to evaluate the long-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson, Eric L., Silverberg, Jonathan I., Nosbaum, Audrey, Winthrop, Kevin L., Guttman-Yassky, Emma, Hoffmeister, Karin M., Egeberg, Alexander, Valdez, Hernan, Zhang, Min, Farooqui, Saleem A., Romero, William, Thorpe, Andrew J., Rojo, Ricardo, Johnson, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370859/
https://www.ncbi.nlm.nih.gov/pubmed/34406619
http://dx.doi.org/10.1007/s40257-021-00618-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370859/
https://www.ncbi.nlm.nih.gov/pubmed/34406619
http://dx.doi.org/10.1007/s40257-021-00618-3

Ejemplares similares